Givinostat Shows Extended Ambulation in DMD Patients, MRI Data Released

Givinostat, an oral HDAC inhibitor approved for DMD in 2024, shows extended ambulation (median age 17.3 years vs. 11.0–13.4 year benchmark) and quantitative MRI evidence of reduced muscle fat infiltration in Phase 3 extension data presented at ICNMD 2026. The mutation-agnostic mechanism and durable safety profile position it as a platform therapy ahead of Health Canada regulatory decision.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.